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Introduction
Sjögren’s syndrome (SS) is a chronic disease aﬀ  ecting 
mainly the exocrine glands, but any organ or system of 
the body can be involved. SS can occur alone or in 
association with other autoimmune rheumatic diseases. 
A great deal of evidence supports the autoimmune nature 
of the disease: aggressive tissue inﬁ  ltration by lympho-
cytes, a plethora of circulating autoantibodies, antibodies 
that cross the placenta and induce disease in the fetus, 
female preponderance, familial clustering with other 
autoimmune disorders, a strong association with speciﬁ  c 
human leukocyte antigen (HLA) alleles, and common 
clinical features with other autoimmune rheumatic 
diseases, such as arthritis, Raynaud phenomenon, and 
serositis [1]. Th  erefore, researchers characterized SS as 
autoimmune epithelitis [2].
SS is characterized by lymphocytic inﬁ  ltration of the 
exocrine glands, such as salivary and lacrimal glands, 
where lymphocytes are not normally found. Lymphocytic 
inﬁ  ltration leads to glandular dysfunction and the main 
clinical manifestations of SS (that is, oral and ocular 
dryness) (xerostomia and keratoconjunctivitis sicca). 
About 30% of patients with primary SS develop extra-
glandular manifestations, including Raynaud pheno  me-
non, peripheral neuropathy, vasculitis, hypergamma-
globulinemic purpura, and hyperviscosity syndrome, as 
well as involvement of thyroid, lungs, kidneys, and liver. 
Th   e worst outcome in a lymphocytic inﬁ  ltrative disorder, 
such as SS, is the development of a lymphoproliferative 
disease, especially B-cell lymphoma, which occurs in 
approxi  mately 5% of patients with SS. Anti-nuclear anti-
bodies and various serum autoantibodies, such as anti-
SS-A (Ro) and SS-B (La) antibodies, are usually detected 
in patients with SS [1].
Th  e pathogenesis of primary SS is a multi-factorial 
process leading to damage and dysfunction of the 
exocrine glands and other target organs. Environmental 
factors (such as a viral infection) aﬀ   ect the exocrine 
glands and stimulate dendritic or glandular cells to 
activate the HLA-independent ‘innate immune system’, 
which uses Toll and Toll-like receptors that recognize 
pathogen-speciﬁ   c epitopes. Th  is process leads to up-
regulation of adhesion proteins and production of 
chemo  kines by the local epithelial cells, which become 
activated and act as antigen-presenting cells [3]. Lympho-
cytes migrate into the gland in response to chemokines, 
adhere to vascular adhesion molecules, and interact with 
dendritic and epithelial cells. Local production of cyto-
kines, especially type I and type II interferons (IFNs), 
leads to perpetuation of the immune response and 
continuous stimulation of T and B cells, which may lead 
to gene mutations in B cells and lymphoma development. 
Overproduction of immunoglobulins, production of 
auto  antibodies, and memory lymphocytes are also conse-
quences of the aberrant activation of cellular immunity. 
Subsequent activation of tissue damage mechanisms, 
such as apoptosis, results in chronic inﬂ  ammation of the 
aﬀ  ected glands, ﬁ  brosis, and loss of normal function [4].
Viruses can trigger autoimmune reactions in both 
humans and experimental animals through several 
mechanisms. Th  e most important mechanisms are the 
virus-induced neoantigen expression, the molecular 
mimicry between viral and host antigens which results in 
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Circumstantial evidence suggests that retroviruses 
play a role in the pathogenesis of Sjögren’s syndrome. 
Such evidence, derived from studies of patients 
with Sjögren’s syndrome, includes the following: the 
presence of serum antibodies cross-reactive with 
retroviral Gag proteins; the occurrence of reverse 
transcriptase activity in salivary glands; the detection 
of retroviral antigens, retrovirus-like particles, or novel 
retroviral sequences in salivary glands; the occurrence 
of Sjögren’s syndrome-like illnesses in patients having 
confi  rmed systematic infections with retroviruses 
such as human immunodefi  ciency virus-1 (HIV-1) and 
human T lymphotropic virus type 1; and the benefi  cial 
eff  ect of anti-retroviral treatment on the occurrence of 
HIV-1-associated sicca syndrome. Additional evidence 
is provided by animal models.
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clones (or both) targeting host tissues, and ﬁ  nally abnor-
malities in cytokine production which are caused by the 
viral infection. Although the etiology of SS is multi-
factorial, it appears that environmental factors trigger the 
syndrome in genetically predisposed individuals. Viral 
infections are the best candidates for the role of 
environmental triggers, and a number of observations 
support this notion [5]. For instance, the La/SSB antigen 
is increased in the nucleus, cytoplasm, and cell 
membrane of cells infected by viruses. Th   e La antigen, a 
target of autoanti  body production in SS, is involved in 
processing viral RNA. Similar increased concentrations 
were observed in acinic and conjunctival epithelial cells 
of patients with SS but not in healthy controls or patients 
with rheumatoid arthritis. Recent studies revealed a 
major role for activation of the type I IFN pathway in the 
pathogenesis of SS, as evidenced by the increased 
circulating type I IFN activity and an IFN ‘signature’ in 
peripheral blood mononuclear cells and minor salivary 
gland biopsies from these patients, a ﬁ  nding that further 
supports the idea of viral involvement in SS pathogenesis 
[6]. Early studies pointed to Epstein-Barr virus and 
cytomegalo  virus as the triggering agents of SS. During 
the last decade, retroviruses [7] and enteroviruses [8] 
came into the spotlight.
Retroviruses are capable of infecting cells of the 
immune system, leading to destruction or stimulation of 
T cells, increased production of antibodies, and ulti-
mately to heavy immunosuppression, making the patient 
vulnerable to opportunistic infections and malignancies, 
such as lymphomas. Several lines of epidemiological, 
serological, and experimental evidence have suggested 
that retroviral infections – especially those due to human 
T lymphotropic virus type 1, human immunodeﬁ  ciency 
viruses (HIVs), human intracisternal A-type retroviral 
particle (HIAP-I), and human retrovirus-5 (HRV-5) – are 
implicated as the triggering factors for the development 
of SS (Table 1). Th   e aim of this review is to summarize 
the existing data on the role of retroviruses in the etio-
pathogenesis of SS and delineate possible implications for 
the development of more eﬀ  ective treatment strategies.
Human T lymphotropic virus type 1
Human T lymphotropic virus type 1 (HTLV-1), the ﬁ  rst 
human retrovirus to be discovered [9], causes two usually 
fatal diseases: adult T-cell leukemia/lymphoma [10] and 
HTLV-I-associated myelopathy (HAM) [11], the latter of   
which is also known as tropical spastic paraparesis. 
HTLV-1 is endemic in southern Japan, the Caribbean, 
South America, the Middle East, and southern Africa and 
is estimated to infect 10 to 20 million people worldwide 
[12]. Seroprevalence in endemic areas ranges from 3% to 
5% in Trinidad and is as high as 30% in southern Japan [12].
In the ’80s, an association between SS and HTLV-I 
infection was suggested by clinical reports and experi-
mental data from murine animal models [5]. Initial clinical 
reports described some HTLV-I-infected patients who had 
tropical spastic paraparesis and who developed an SS-like 
illness [13]. Another report showed the presence of an 
antigen reactive with a monoclonal antibody to HTLV-I 
p19 in the minor salivary glands of patients with SS [14].
Th  e possible association between HTLV-1 infection 
and SS, suggested by these initial observations, led to 
serological studies for the prevalence of antibodies to 
HTLV-I in patients with primary SS. In a study conducted 
in the Nagasaki Prefecture of Japan, which is endemic for 
HTLV-I infection, Eguchi and colleagues [15] examined 
serum samples from 36 consecutive patients with 
primary SS and found – by enzyme-linked immuno-
sorbent assay, particle agglutination assay, and Western 
blotting – that 13 (36%) were positive for antibodies to 
HTLV-I.
In another study, among 74 SS patients from the same 
area, the HTLV-1 seroprevalence rate was 23% (17/74), 
signiﬁ  cantly higher than that among blood donors (3%, 
or 916/27,284), whereas the diﬀ  erence between patients 
with systemic lupus erythematosus (SLE) and blood 
donors was insigniﬁ   cant. Salivary IgA antibodies to 
HTLV-1 were common among seropositive patients with 
SS (5/7), and this might be due to increased viral activity 
in the salivary glands. Th  ese antibodies were barely 
detectable in patients with HAM (prevalence of 1/10) or 
in healthy carriers (0/11) [16]. In response to the above-
mentioned report, Coulderc and colleagues [17] studied 
11 patients who had primary SS and who were living in a 
non-endemic area (France), and detected anti-tax 
antibodies in 2 to 5 serum samples (depending on the 
technique), a ﬁ  nding suggesting that tax sequences of 
HTLV-1 might be implicated in the pathogenesis of SS. 
Th  e detection of antibodies to HTLV-I proteins in SS 
patients from both endemic and non-endemic areas 
might suggest that other endogenous retroviruses are the 
etiological agents and that the occur  rence of antibodies 
against HTLV-I is due to cross-reactivity between 
endogenous retroviral and HTLV-I proteins.
Sasaki and colleagues [18] examined the T-cell receptor 
(TCR) Vbeta gene usage by the inﬁ  ltrating lymphocytes 
in the labial salivary glands (LSGs) from the HTLV-I-
seropositive and HTLV-I-seronegative (idio  pathic) patients 
with SS. Th  e authors found accumulation of HTLV-I-
infected T cells expressing TCR with a conserved motif 
in both HTLV-I-associated and idio  pathic SS [18]. In 
another study among HTLV-I-sero  positive patients with 
SS, HTLV-I proviral DNA in the LSG was detected by 
polymerase chain reaction (PCR) and the localization of 
the viral DNA in the LSG was examined by in situ PCR 
hybridization [19]. Th   e cellular DNA extracted from the 
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present in the nucleus of the inﬁ  ltrating T cells but not in 
the epithelial or the acinar cells of the salivary glands. 
Furthermore, the viral loads in the LSG were 
approximately 8 to 9 × 103 times higher than those in the 
peripheral blood mononuclear cells. Th   ese studies, taken 
together, support the hypo  thesis that HTLV-1-infected T 
lymphocytes inﬁ  ltrate the salivary glands and initiate the 
pathogenetic mechanisms of SS.
Th  e association of HTLV-1 with SS was indirectly 
shown in another Japanese study, which reported a high 
prevalence of SS in patients with HAM [20]. Ten 
Table 1. Studies providing evidence on the role of retroviruses in the pathogenesis of Sjögren’s syndrome
Retrovirus Study  Origin  Main  fi  ndings
HTLV-1    
  [12]  USA  SS-like illness developed in HTLV-I-infected patients with tropical spastic paraparesis.
  [13]  Europe  An antigen reactive with a monoclonal antibody to HTLV-I p19 was present in the LSG of patients with SS. 
  [14]  Japan  Thirty-six percent of patients with primary SS were found, by ELISA, to be positive for serum antibodies to HTLV-I. 
  [15]  Japan  Rates of HTLV-1 seroprevalence were 23% (17/74) among patients with SS and 3% (916/27,284) among blood 
      donors. However, the diff  erence between patients with systemic lupus erythematosus and blood donors was 
     insignifi   cant.
  [17]   Europe  Serum antibodies to HTLV-I were detected in 2 to 5 out of 11 patients with SS.
  [18]  Japan  HTLV-I-infected T cells expressing TCR with a conserved motif accumulated in both HTLV-I-associated and 
     idiopathic  SS.
  [19]  Japan  HTLV-I proviral DNA was present in the nucleus of the infi  ltrating T cells but not in either the epithelial cells or the 
      acinar cells of the salivary glands of HTLV-I-seropositive patients with SS. 
  [20]  Japan  Defi  nitive SS was diagnosed in 6 patients and probable SS in 2 patients among 10 patients with HAM.
  [21]  Japan  Defi  nite SS was diagnosed in 13 out of 20 patients with HAM.
 [22]  Japan  The  HTLV-I  tax gene, but not the HTLV-I gag, pol, or env genes, was detected in LSG samples from 4 out of 14 
      patients with SS. 
 [23]  Europe  The  HTLV-I  tax gene, but not the gag, pol, or env genes, was detected in LSG sections from 2 out of 9 patients 
      with SS and from none of the control subjects.
 [24]  Europe  The  tax gene of HTLV-I was detected in LSG from 15 out of 50 of patients (30%) with SS, 9 out of 32 patients 
      (28%) with other infl  ammatory processes (3/9 graft-versus-host disease, 5/19 extravasated cysts, and 
      1/4 sarcoidosis), and only 1 out of 26 patients (4%) with normal LSG.
 [25]  Japan  The  HTLV-I  tax gene was detected in LSG of 3 out of 17 seronegative patients (18%) with SS.
  [42]  USA  An autoimmune exocrinopathy with histopathological fi  ndings similar to those of SS was observed in HTLV-1 tax 
     transgenic  mice.
HIV-1    
  [27]  USA  An SS-like illness was reported among HIV-1-infected patients.
  [28,29]  USA  The DILS was described as a disorder aff  ecting a subgroup of patients with HIV-1 infection.
  [30]  Europe  The prevalence of DILS among HIV-1-infected patients was 7.79%. 
  [31]  USA  The prevalence of DILS among HIV-1-infected patients was 32.3%. 
  [32]  USA-Africa  The prevalence of DILS in patients from the US was 6%. The prevalence in patients with HIV infection from 
      Cameroon was 48%.
  [33]  Europe  The prevalence of HIV-1-related SS dropped from 8% in the pre-HAART era to 1.5% in the post-HAART era.
  [34]  USA  The prevalence of DILS dropped signifi  cantly in the post-HAART era.
HIAP-I    
  [37]  USA  HIAP-I has been identifi  ed in lymphoblastoid cells cocultured with homogenates of salivary glands from patients 
     with  SS.
HRV-5    
  [40]  Europe  Novel sequences spanning parts of the protease and reverse transcriptase open reading frames of a retrovirus 
      were detected in LSG tissues of eight patients with SS.
  [41]  Europe  Two out of 55 LSG samples from patients with SS were positive for HRV-5 proviral DNA.
DILS, diff  use infi  ltrative lymphocytosis syndrome; ELISA, enzyme linked immunosorbent assay; HAART, highly active anti-retroviral treatment; HAM, HTLV-I (human 
T lymphotropic virus type 1)-associated myelopathy; HIAP-I, human intracisternal A-type retroviral particle; HIV-1, human immunodefi  ciency virus-1; HRV-5, human 
retrovirus-5; HTLV-1, human T lymphotropic virus type 1; LSG, labial salivary gland; SS, Sjögren’s syndrome; TCR, T-cell receptor.
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the preliminary criteria for SS which were proposed by the 
European Community, deﬁ  nitive SS was diagnosed in 6 
patients and probable SS was diagnosed in 2 patients. In a 
follow-up study from the same investigators, deﬁ  nite SS 
was diagnosed in 13 out of 20 patients with HAM [21].
Serological studies prompted the search for HTLV-1 
genes in salivary glands of patients with SS. Two groups, 
one European and the other Japanese, have independently 
conﬁ  rmed the presence of HTLV-I genome in salivary 
gland tissue from patients with SS [22,23]. In both cases, 
only the tax gene was detectable, whereas pol, gag, and 
env genes were not present. In the Japanese study, the 
HTLV-I tax gene, but not the HTLV-I gag, pol, or env 
genes, was detected in LSG samples from 4 out of 14 
patients (29%) [22]. Similarly, European investigators, 
using  in situ hybridization and PCR, detected the tax 
gene, but not the gag, pol, or env genes, of HTLV-I in LSG 
sections from 2 out of 9 patients (22%) with SS and from 
none of the control subjects [23]. In a follow-up study, 
the same group [24], using PCR, studied LSG tissues 
from 50 patients with deﬁ  nite SS and from 58 controls 
(32 patients with LSG associated with other inﬂ  ammatory 
processes and 26 patients with normal LSG). Th  e tax 
gene of HTLV-I was detected in LSG from 15 out of 50 
patients (30%) with SS but also in specimens from 9 out 
of 32 patients (28%) with LSG involved by other 
inﬂ   ammatory pro  cesses (3/9 graft-versus-host disease, 
5/19 extra  vasated cysts, and 1/4 sarcoidosis) and from 
only 1 out of 26 patients (4%) with normal LSG. A 
652-base pair region, sequenced in 2 patients with SS, 
was 98% to 98.5% homolo  gous to the canonic sequence 
of  tax HTLV-I. Once more, HTLV-I gag,  pol, and env 
genes were never detected. Th  e  ﬁ  ndings of the European 
study support a non-speciﬁ  c role for the HTLV-1 tax 
gene in the pathogenesis of SS since low numbers of 
copies are detected also in other inﬂ  ammatory processes.
Interestingly, in a report from Japan [25], an HTLV-I 
endemic area, HTLV-I tax sequence was detected in LSG 
of only 3 out of 17 seronegative patients (18%) with SS, 
which is unexpectedly less frequent than in patients from 
Europe, which is an HTLV-I non-endemic area. More-
over, PCR revealed that the copy number of the HTLV-I 
tax in the gland tissue of these seronegative patients was 
very low and therefore unlikely to be suﬃ   cient  to 
promote an inﬂ  ammatory reaction in the tissue. Th  ese 
ﬁ  ndings might argue against the involvement of HTLV-I 
in the pathogenesis of SS in Asian seronegative patients. 
Th  e discrepancies between the European and Japanese 
studies suggest that HTLV-1, along with other environ-
mental and genetic factors, might be a cofactor in the 
pathogenesis of SS.
It is possible that the failure to detect retroviral genes, 
other than tax, is the result of technical malfunctions or 
contamination issues. However, the similarity of the 
results deriving from two independent groups points to 
an alternative explanation: patients with SS were infected 
with a defective virus in which all genes, but tax, have 
been deleted. Defective HTLV-I proviruses have been 
shown to contribute to the pathogenesis of hematological 
malignant diseases, such as mycosis fungoides and 
HTLV-I-associated T-cell leukemia [26]. It is noteworthy 
that both studies, in contrast to the above-mentioned 
serological studies, failed to detect serum antibodies to 
HTLV-I in any of the studied patients with SS. Th  e  cause 
of this discrepancy is not clear; possibly, production of 
antibodies to HTLV-1 characterizes only a subgroup of 
patients with SS.
Human immunodefi  ciency virus-1
Early after the outbreak of the HIV epidemic, cases of an 
SS-like illness were reported among HIV-1-infected 
patients [27]. A few years later, the sicca syndrome asso-
ciated with HIV-1 infection was deﬁ   ned as a discrete 
disease entity named diﬀ  use inﬁ  ltrative  lymphocytosis 
syndrome (DILS) [28,29]. DILS, a disorder aﬀ  ecting a 
subgroup of patients with HIV-1 infection, is almost 
indistinguishable from SS, with bilateral parotid and 
lacrimal glandular swelling, xerostomia, and kerato-
conjunctivitis of varying intensity, frequently accom-
panied by persistent CD8 peripheral lymhocytosis and 
visceral inﬁ   ltration by CD8+ T lymphocytes. Th  is dis-
order diﬀ  ers from SS in that in the former the inﬁ  ltrate in 
the salivary glands consists predominantly of CD8+ T 
cells (in contrast to primary SS, in which the inﬁ  ltrate 
consists predominantly of CD4+ lymphocytes), anti-Ro 
and anti-La autoanti  bodies are seen less frequently, males 
are three times more likely to be infected [30], there are 
commonly numerous extraglandular manifestations such 
as lympho  cytic pneumonitis, and there are diﬀ  erent HLA 
associations (HLA-DR5 and DR6) [29]. Th  e diﬀ  erences 
between DILS and SS might suggest diﬀ  erent  patho-
genetic mecha  nisms. However, the predominantly CD8+ 
inﬁ  ltrates in DILS might be explained by the fact that 
HIV-1 infection is characterized by CD4+ lympho  cyto-
penia and a relative CD8+ lymphocytosis. Th  e excess of 
males in the Greek cohort of patients is also expected 
since the majority of HIV-1-infected patients in 
developed countries are males.
Th   e prevalence of DILS among HIV-1-infected patients 
diﬀ   ers in published studies among diﬀ  erent  ethnic 
groups, a ﬁ   nding suggesting that HIV-1, along with 
genetic factors, might trigger the pathogenetic mecha-
nisms of sicca. In a predominantly male, Greek cohort, 
the overall prevalence was 7.79%, which is more than 
2.5  times higher than that observed in normal Greek 
adult females [30]. In a larger cohort from the US, where 
diﬀ  erent  deﬁ   nitions and methodology were used, the 
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histological study of minor salivary glands from 164 HIV-
positive or -negative patients from Cameroon or the US 
showed a DILS prevalence of as high as 48% in patients 
with HIV infection from Cameroon but of only 6% in 
patients from the US. Th  is striking diﬀ  erence  was 
attributed to the fact that all African patients were 
treatment-naïve whereas 76% of American HIV-positive 
patients had received anti-retroviral therapy [32].
Th   ese data underline the impact of highly active anti-
retroviral treatment (HAART) on the prevalence of DILS. 
A successful HAART reduces viral replication, viral load 
in the peripheral blood falls to undetectable levels, the 
number of CD4+ T lymphocytes increases, and ﬁ  nally 
reconstitution of the immune system occurs. In a follow-
up study, the prevalence of HIV-1-related SS dropped 
from 8% in the pre-HAART era to 1.5% (2 out of 131 
patients) after the introduction of HAART [33]. Similar 
data were reported in a study from the US, where the 
prevalence of DILS had dropped signiﬁ  cantly in the post-
HAART era [34]. Th  is  beneﬁ  cial eﬀ  ect of HAART on the 
prevalence of DILS is indirect evidence that HIV-1 
contributes to the pathogenesis of the HIV-1-associated 
sicca. If the virus per se infects the salivary glands 
triggering the pathogenetic mechanisms, it is quite 
logical that inhibition of viral replication and reduction 
of viral load lead to a reduction in the prevalence of DILS. 
However, a researcher from Italy reported that, in a 
cohort of 150 HIV-1-infected patients, 4 developed an 
SS-like illness, with positive salivary gland biopsy, 6 to 48 
months after initiation of HAART [35]. In other words, 
an SS-like syndrome was rather a complication of 
HAART. Th  ese contradictory data on the eﬀ  ect  of 
HAART might reﬂ  ect the complexity of the pathogenetic 
mechanisms involved in the sicca syndrome associated 
with HIV-1 infection.
Other retroviruses
Th   e presence of a syndrome resembling SS in a subgroup 
of patients with HIV-1 infection was another indirect 
piece of evidence that retroviruses might be the trigger-
ing environmental factor for the development of SS. 
Th  erefore, there was an eﬀ   ort to detect antibodies to 
retroviral proteins or retroviral antigens or both in HIV-
negative patients with primary SS. In a pivotal study, 
Talal and colleagues [7] performed immunoblotting 
against HIV-1 proteins by using sera from 47 HIV-1-
seronegative patients with primary SS. Moderate-to-
strong reactivity, suggesting the presence of serum anti-
bodies, was found in 14 patients (30%). Of 120 normal 
subjects, only 1 showed moderate positivity. All 14 
positive SS sera reacted against p24 (gag), which is a 
group-speciﬁ  c protein, but failed to react against gp41 or 
gp120 (env). Interestingly, only 1 of the 14 sera reacted 
against Ro (SS-A), and 1 other reacted against La (SS-B). 
Th  ese data suggest the presence of a subgroup of SS 
patients who resemble patients with HIV-1-induced SS-
like disease. It should be noted that, in a subsequent 
study, serum antibodies to the p24 gag protein of HIV-1 
were detected in 22 out of 61 patients (36%) with SLE, a 
ﬁ  nding suggesting that reactivity to retroviral proteins is 
a phenomenon not speciﬁ  c to SS [36].
Th  e reactivity of SS sera against only a group-speciﬁ  c 
antigen of HIV-1 raised the possibility that the retrovirus 
implicated in the pathogenesis of SS was not HIV-1 per 
se  but an HIV-1-like retrovirus. Garry and colleagues 
[37] reported that an HIAP-I that is antigenically related 
to HIV-1 has been identiﬁ   ed in lympho  blastoid cells 
cocultured with homogenates of salivary glands from 
patients with SS. HIAP-I shares a limited number of 
antigenic epitopes with HIV-1 but is distin  guishable by 
morphological, physical, and bio  chemical criteria. A 
second type of human intracisternal A-type retrovirus, 
HIAP-II, was detected in a subset of patients with 
idiopathic CD4 lymphocytopenia (ICL), an AIDS-like 
immunodeﬁ   ciency disease [38]. Most patients with 
HIAP-II-positive ICL were also antinuclear 
antibody-positive.
A subsequent report showed that sections of the minor 
salivary glands from 31% of patients with primary SS 
contained an epithelial cytoplasmic protein reactive with 
a monoclonal antibody to the p19 group-speciﬁ  c antigen 
(gag) of HTLV-1 [14]. Serum antibodies to HTLV-1 were 
negative, conﬁ   rming that the antigen was not part of 
HTLV-1. Th   e antigen showed properties consistent with 
an endogenous retrovirus in that it was absent in healthy 
tissues or resting cells.
Similar results were reported in a study from Japan, 
where retroviruses were sought in LSGs and peripheral 
blood mononuclear cells from patients with SS by 
immunoblotting assay, immunohistochemical assay, 
PCR, reverse transcriptase (RT) activity assay, and trans-
mission electron microscopy [39]. Sera from 5 out of 15 
patients (33%) with SS reacted against the p24 (gag) 
antigen of HIV-1. LSG biopsy specimens from 7 of the 15 
patients (47%) with SS contained an epithelial cyto-
plasmic protein reactive with a monoclonal antibody to 
the p24 antigen of HIV-1. RT activity was detected in the 
salivary gland tissues in 3 out of 10 patients. Transmission 
electron microscopy revealed the presence of A-type-like 
retroviral particle epithelial cells of salivary glands. Th  ese 
data suggested the presence of an unknown retrovirus 
that is similar to HIV-1 in the salivary gland and that 
might be involved in the pathogenesis of SS in a 
subpopulation of patients with SS.
Another group, using a PCR-based strategy, detected 
novel sequences spanning parts of the protease and RT 
open reading frames of a retrovirus in salivary gland 
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related to that of type B and type D retroviruses and was 
present in a sucrose density gradient fraction corres-
ponding to that of an enveloped retrovirus particle. Th  e 
researchers suggested that the sequence represents an 
infectiously acquired genome, provisionally called HRV-5. 
However, a follow-up study failed to show an association 
of HRV-5 infection with SS [41]. Out of 55 salivary gland 
samples from SS patients tested by nested PCR, only 2 
were positive for HRV-5 proviral DNA. One possible 
explanation could be that, owing to the extremely low 
virus load in minor salivary glands, the number of HRV-
5-infected patients may be under  estimated.
Animal models
An autoimmune exocrinopathy with histopathological 
ﬁ  ndings similar to those of SS was observed in HTLV-1 
tax transgenic mice [42]. After the insertion of the tax 
gene, the animals develop a spontaneous sialadenitis 
characterized by focal proliferation of ductal epithelial 
cells within the major and minor salivary glands followed 
by lymphocytic inﬁ  ltration. A direct association between 
the expression of tax protein and the extent of the histo-
logical damage of the salivary glands was noticed. In 
another animal model, exocrinopathy resembling SS was 
induced in mice injected intraperitoneally with another 
murine retrovirus, the LP-BM5 murine leukemia virus 
[43].
Therapeutic implications
Steinfeld and colleagues, on the basis of the accumulating 
evidence for a role for retroviruses in the pathogenesis of 
SS as well as the clinical observation that the 
administration of zidovudine (AZT) in some patients 
with DILS led to diminution of parotid gland enlargement 
and overall improvement of sicca symptoms [44], 
undertook an open-label study evaluating the eﬃ   cacy of 
AZT in seven patients with primary SS [45]. AZT, the 
ﬁ  rst anti-retroviral agent to be approved for the treat-
ment of HIV-1 infection, is a thymidine analog that 
reduces viral replication by inhibiting the viral RT. 
Treatment resulted in signiﬁ   cant improvement in all 
sub  jective manifestations as well as the objective 
parameters of ocular dryness. Th  e clinical beneﬁ  t 
persisted in 5 out of 7 patients 1 month after the end of 
therapy [45]. Owing to the possible placebo eﬀ  ect, a 
common bias in open-label studies of drugs in primary 
SS, the results of this study should be interpreted with 
caution.
On the basis of these promising preliminary data, 
Gescuk and colleagues [46] conducted a placebo-con-
trolled, randomized, double-blind study of lamivudine in 
primary SS. Lamivudine is a synthetic nucleoside RT 
inhibitor that inhibits replication of human retroviruses. 
Sixteen patients with primary SS were randomly assigned 
to receive either lamivudine 150 mg twice daily or 
placebo for 3 months. Treatment with lamivudine did not 
result in signiﬁ  cant improvement in the primary outcome 
measure of unstimulated whole salivary ﬂ   ow or other 
secondary measures, including minor salivary gland 
biopsy focus scores. However, the study enrolled small 
numbers of subjects and thus might not have been 
powered to detect subtle diﬀ  erences.
Th  e contradictory results for these two RT inhibitors 
may be due to the fact that retroviral infections can be 
treated eﬀ   ectively not with a single agent but with a 
combination of active anti-retroviral agents. Th   e fact that 
the prevalence of DILS has been reduced signiﬁ  cantly in 
the post-HAART era [33,34] points in this direction.
Conclusions and future directions
Circumstantial evidence suggests that retroviruses are 
candidates for the initiation or maintenance of auto-
immunity in SS. Such evidence includes the presence of 
antibodies that are cross-reactive with retroviral Gag 
proteins in patients with SS, the detection of retroviral 
antigens in patients with SS, the isolation of retrovirus-
like particles or novel retroviral sequences from salivary 
glands of patients with SS, the occurrence of SS-like 
illnesses in patients having conﬁ   rmed infections with 
known retroviruses such as HIV-1 and HTLV-1, the 
beneﬁ  cial eﬀ  ect of HAART on the occurrence of HIV-1-
associated sicca syndrome, and the occurrence of RT 
activity in salivary glands of patients with SS. Additional 
evidence is provided by animal models; HTLV-1 tax 
transgenic mice develop sieladenitis characterized by 
lymphocytic inﬁ  ltration.
On the other hand, serum antibodies that are cross-
reactive with retroviral Gag proteins have been described 
in other autoimmune diseases, such as SLE. None of the 
patients with SS has signs or symptoms of a systematic 
viral infection and there is no evidence for vertical or 
sexual transmission of a virus in patients with SS, all of 
which are characteristics of well-known retroviral 
diseases such as HIV-1 or HTLV-1 infection. Th  e  hypo-
the  sis that the culprit is a defective retrovirus, not able to 
cause systematic disease or to be transmitted, remains to 
be proven.
In conclusion, existing evidence suggests that retro-
viruses, along with other environmental and genetic 
factors, might play a pathogenetic role in a subpopulation 
of patients with SS. Future research should better deﬁ  ne 
and characterize this subpopulation, delineate the impli-
cated pathogenetic mechanisms, develop new diagnostic 
tools to accurately recognize patients with retrovirus-
associated SS, and design new therapeutic approaches, 
possibly using combinations of newer anti-retroviral 
agents.
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